Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis
Open Access
- 7 September 2019
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 25 (33) , 4933-4944
Abstract
Proton pump inhibitors (PPIs) are widely prescribed, often without clear indications. There are conflicting data on its association with mortality risk and hepatic decompensation in cirrhotic patients. Furthermore, PPI users and PPI exposure in some studies have been poorly defined with many confounding factors. To examine if PPI use increases mortality and hepatic decompensation and the impact of cumulative PPI dose exposure. Data from patients with decompensated liver cirrhosis were extracted from a hospital database between 2013 to 2017. PPI users were defined as cumulative defined daily dose (cDDD) ≥ 28 within a landmark period, after hospitalisation for hepatic decompensation. Cox regression analysis for comparison was done after propensity score adjustment. Further risk of hepatic decompensation was analysed by Poisson regression. Among 295 decompensated cirrhosis patients, 238 were PPI users and 57 were non-users. PPI users had higher mortality compared to non-users [adjusted HR = 2.10, (1.20-3.67); P = 0.009]. Longer PPI use with cDDD > 90 was associated with higher mortality, compared to non-users [aHR = 2.27, (1.10-5.14); P = 0.038]. PPI users had a higher incidence of hospitalization for hepatic decompensation [aRR = 1.61, (1.30-2.11); P < 0.001]. PPI use in decompensated cirrhosis is associated with increased risk of mortality and hepatic decompensation. Longer PPI exposure with cDDD > 90 increases the risk of mortality.Keywords
This publication has 32 references indexed in Scilit:
- Diabetes, Plasma Glucose, and Incidence of Fatty Liver, Cirrhosis, and Liver Cancer: A Prospective Study of 0.5 Million PeopleHepatology, 2018
- Gut Microbiota and Complications of Liver DiseaseGastroenterology Clinics of North America, 2017
- Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascitesHepatology, 2016
- Proton pump inhibitors affect the gut microbiomeGut, 2015
- Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover TrialGastroenterology, 2015
- Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?Expert Review of Gastroenterology & Hepatology, 2015
- Type 2 diabetes: A risk factor for liver mortality and complications in hepatitis B cirrhosis patientsJournal of Gastroenterology and Hepatology, 2015
- Altered profile of human gut microbiome is associated with cirrhosis and its complicationsJournal of Hepatology, 2014
- Proton Pump Inhibitors and Risk of 1-Year Mortality and Rehospitalization in Older Patients Discharged From Acute Care HospitalsJAMA Internal Medicine, 2013
- Effect of body mass index and alcohol consumption on liver disease: analysis of data from two prospective cohort studiesBMJ, 2010